References
Abraham PF, Calabrese JR (2008) Evidenced-based pharmacologic treatment of borderline personality disorder: a shift from SSRIs to anticonvulsants and atypical antipsychotics? J Affect Disord 111:21–30
Adityanjee RA, Brown E, Thuras P, Lee S, Schulz SC (2008) Quetiapine in patients with borderline personality disorder: an open-label trial. Ann Clin Psychiatry 20:219–226
Barzman DH, DelBello MP, Adler CM, Stanford KE, Strakowski SM (2006) The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s). J Child Adolesc Psychopharmacol 16:665–670
DeHert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU (2011) Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Neuropsychopharmacol 21:144–158
DelBello MP, Chang K, Welge JA, Adler CM, Rana M, Howe M, Bryan H, Vogel D, Sampang S, Delgado SV, Sorter M, Strakowski SM (2009) A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 11:483–493
Findling RL, Reed MD, O’Riordan MA, Demeter CA, Stansbrey RJ, Mcnamara NJ (2007) A 26-week open-label study of quetiapine in children with conduct disorder. J Child Adolesc Psychopharmacol 17:1–9
Zuddas A, Zanni R, Usala T (2011) Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol 21:600–620
Acknowledgements
This work was supported by the Croatian Ministry of Science, Education and Sport (MSES), grant number 098-0982522-2455. The comments in this work are solely the responsibility of the authors and do not necessarily represent the official views of the MSES. All protocols were approved by hospital review board and the Ethics Committee of the Psychiatric Hospital for Children and Youth Zagreb and were therefore in line with the guidelines of the Declaration of Helsinki.
Conflict of interest
All authors declared no financial relationship with the Organization that sponsored the research, and have no conflict of interest.
Disclosure
All authors have made a significant contribution to the conception and design or the analysis and interpretation of data, have participated in drafting the article or reviewing and/or revising it for intellectual content and have approved the final version of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Podobnik, J., Foller Podobnik, I., Grgic, N. et al. The effect of add-on treatment with quetiapine on measures of depression, aggression, irritability and suicidal tendencies in children and adolescents. Psychopharmacology 220, 639–641 (2012). https://doi.org/10.1007/s00213-011-2607-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-011-2607-7